Richard C. Mohs
#106,242
Most Influential Person Now
Richard C. Mohs's AcademicInfluence.com Rankings
Richard C. Mohsmedical Degrees
Medical
#1332
World Rank
#1658
Historical Rank
Neurology
#117
World Rank
#179
Historical Rank
Richard C. Mohspsychology Degrees
Psychology
#2054
World Rank
#2411
Historical Rank
Neuropsychology
#44
World Rank
#47
Historical Rank
Cognitive Psychology
#160
World Rank
#165
Historical Rank
Download Badge
Medical Psychology
Why Is Richard C. Mohs Influential?
(Suggest an Edit or Addition)Richard C. Mohs's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease (2011) (12716)
- Current concepts in mild cognitive impairment. (2001) (4482)
- A new rating scale for Alzheimer's disease. (1984) (3825)
- The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assesment of Alzheimer's disease (1989) (3628)
- Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. (2002) (3080)
- A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease (1998) (1537)
- Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. (2014) (1327)
- Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. (2000) (1308)
- Practice parameter: Diagnosis of dementia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology (2001) (1258)
- Serotonergic studies in patients with affective and personality disorders. Correlates with suicidal and impulsive aggressive behavior. (1989) (1116)
- The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery (1994) (1012)
- Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. (2004) (917)
- A phase 3 trial of semagacestat for treatment of Alzheimer's disease. (2013) (906)
- Detection of abnormal memory decline in mild cases of Alzheimer's disease using CERAD neuropsychological measures. (1991) (758)
- Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. (1998) (748)
- The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) (1993) (671)
- Development of Cognitive Instruments for Use in Clinical Trials of Antidementia Drugs: Additions to the Alzheimer's Disease Assessment Scale That Broaden Its Scope (1997) (588)
- High, usual and impaired functioning in community-dwelling older men and women: findings from the MacArthur Foundation Research Network on Successful Aging. (1993) (525)
- Detection and staging of dementia in Alzheimer's disease. Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer's Disease. (1992) (519)
- Cholinergic markers in elderly patients with early signs of Alzheimer disease. (1999) (510)
- A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients (2001) (497)
- Physostigmine: improvement of long-term memory processes in normal humans. (1978) (442)
- The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. (1983) (440)
- A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. (1994) (426)
- The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup (2011) (410)
- Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. (1998) (340)
- Consortium to Establish a Registry for Alzheimer’s Disease (CERAD): The first twenty years (2008) (311)
- Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. (1998) (302)
- Positive and negative symptoms in schizophrenia (1984) (293)
- Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. (2007) (290)
- Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease. (1999) (270)
- Drug discovery and development: Role of basic biological research (2017) (267)
- Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. (1982) (264)
- Cortisol and Alzheimer's disease, I: Basal studies. (1986) (251)
- Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease (2012) (248)
- Event-related potentials recorded from young and old adults during a memory retrieval task. (1979) (248)
- Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients (1999) (230)
- Cerebral infarcts in patients with autopsy-proven Alzheimer's disease (1998) (226)
- Reliability of the family history method in genetic studies of Alzheimer's disease and related dementias. (1986) (226)
- Oral physostigmine treatment of patients with Alzheimer's disease. (1985) (222)
- Characteristics of very poor outcome schizophrenia. (1987) (217)
- Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. (1999) (216)
- The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). (1995) (205)
- Alzheimer's Disease Assessment Scale (ADAS). (1988) (205)
- Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease. (2001) (191)
- Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. (2000) (189)
- Plasma homovanillic acid concentration and the severity of schizophrenic illness. (1985) (182)
- Additional support for schizophrenia linkage on chromosomes 6 and 8: a multicenter study. Schizophrenia Linkage Collaborative Group for Chromosomes 3, 6 and 8. (1996) (175)
- Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. (2005) (174)
- Executive dysfunction in Alzheimer disease. (2004) (171)
- Mitochondrial damage in Alzheimer's disease varies with apolipoprotein E genotype (2000) (171)
- Familial aggregation in Alzheimer's disease (1988) (169)
- DONEPEZIL STUDY GROUP. A 24-WEEK, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL OF DONEPEZIL IN PATIENTS WITH ALZHEIMER'S DIS-EASE (1998) (169)
- Practice parameter: Management of dementia (an evidence-based review) (2001) (169)
- Cholinergic approaches to the treatment of Alzheimer's disease. (1986) (162)
- Performance of nonpsychotic relatives of schizophrenic patients on cognitive tests (1994) (151)
- Dr. Siever and Colleagues Reply (1991) (149)
- Cortisol and Alzheimer's disease, II: Dexamethasone suppression, dementia severity, and affective symptoms. (1986) (146)
- Alzheimer's disease. Morbid risk among first-degree relatives approximates 50% by 90 years of age. (1987) (142)
- Functional Decline in Alzheimer's Disease: A Longitudinal Study (1993) (140)
- Cognitive performance in a high-functioning community-dwelling elderly population. (1993) (139)
- Dementia with coexistent major depression. (1989) (135)
- Affective and impulsive personality disorder traits in the relatives of patients with borderline personality disorder. (1991) (134)
- Increased morbid risk for schizophrenia-related disorders in relatives of schizotypal personality disordered patients. (1990) (133)
- Genome scan of schizophrenia. (1996) (129)
- Caspase gene expression in the brain as a function of the clinical progression of Alzheimer disease. (2003) (119)
- Eye tracking, attention, and schizotypal symptoms in nonpsychotic relatives of patients with schizophrenia. (1997) (118)
- Convergence of cognitive and adaptive decline in late-life schizophrenia (1999) (113)
- Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. (2003) (112)
- Age and the dexamethasone suppression test in depression. (1984) (110)
- Neuropsychological test performance in African-American* and white patients with Alzheimer's disease (1995) (110)
- Cognitive functioning in late-life schizophrenia: a comparison of elderly schizophrenic patients and patients with Alzheimer's disease. (1996) (109)
- Clinical and neuropsychological differences between patients with earlier and later onset of Alzheimer's disease (1996) (109)
- Age-related shift in brain region activity during successful memory performance (1998) (105)
- Noncognitive Disturbances in Alzheimer's Disease: Frequency, Longitudinal Course, and Relationship to Cognitive Symptoms (1997) (103)
- Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer's disease assessed by DNA microarray technique (2001) (103)
- Correlates of lateral ventricular size in chronic schizophrenia, I: Behavioral and treatment response measures. (1986) (96)
- Clinical predictors of course for Alzheimer patients in a longitudinal study: a preliminary report. (1988) (93)
- Correlation Between Aβx-40–, Aβx-42–, and Aβx-43–Containing Amyloid Plaques and Cognitive Decline (2001) (92)
- Genome scan of schizophrenia (1998) (90)
- Quality-of-life assessment in dementia drug development. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. (1997) (89)
- Induction of depression with oxotremorine in patients with Alzheimer's disease. (1987) (88)
- The Longitudinal Stability of Cognitive Impairment in Schizophrenia (1995) (88)
- Patterns of risk in first-degree relatives of patients with Alzheimer's disease. (1994) (86)
- Familial aggregation in Alzheimerʼs disease: comparison of risk among relatives of early- and late-onset cases, and among male and female relatives in successive generations (1988) (85)
- RS 86 in the treatment of alzheimer's disease: Cognitive and biological effects (1987) (84)
- The effects of diet and physical activity on plasma homovanillic acid in normal human subjects (1983) (84)
- Longitudinal studies of cognitive, functional and behavioural change in patients with Alzheimer's disease. (2000) (80)
- Discrimination between stages of Alzheimer's disease with subsets of Mini-Mental State Examination items. An analysis of Consortium to Establish a Registry for Alzheimer's Disease data. (1994) (80)
- Neuropeptide abnormalities in patients with early Alzheimer disease. (1999) (79)
- Visuospatial working memory in schizotypal personality disorder patients (2000) (78)
- The Alzheimer's Disease Assessment Scale (1996) (77)
- Elevated Serum Total and LDL Cholesterol in Very Old Patients with Alzheimer’s Disease (2001) (74)
- Contribution of Lewy body inclusions to dementia in patients with and without Alzheimer disease neuropathological conditions. (2000) (74)
- Premorbid sociosexual functioning and long-term outcome in schizophrenia. (1989) (74)
- Empirical assessment of the factorial structure of clinical symptoms in schizophrenic patients: Formal thought disorder (1992) (73)
- A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies (2016) (72)
- A Multicenter Evaluation of New Treatment Efficacy Instruments for Alzheimer's Disease Clinical Trials: Overview and General Results (1997) (71)
- AMPA potentiator treatment of cognitive deficits in Alzheimer disease (2007) (70)
- 4-Aminopyridine in the treatment of alzheimer's disease (1988) (66)
- Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia. (2014) (65)
- 2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease (2014) (65)
- Schizophrenia susceptibility and chromosome 6p24–22 (1995) (64)
- A linkage study of schizophrenia to markers within Xp11 near the MAOB gene (1997) (63)
- A Study of the Reliability of the Family History Method in Genetic Sudies of Alzheimer Disease (1989) (62)
- A study of the efficacy of a comprehensive memory enhancement program in healthy elderly persons (1998) (61)
- The future is now: Model‐based clinical trial design for Alzheimer's disease (2015) (61)
- Evidence of a locus for schizophrenia and related disorders on the short arm of chromosome 5 in a large pedigree. (1996) (60)
- Clinical Studies of the Cholinergic Deficit in Alzheimer's Disease (1985) (60)
- Control of exogenous factors affecting plasma homovanillic acid concentration (1987) (60)
- Enhancement of memory by physostigmine. (1979) (60)
- L-dopa challenge and relapse in schizophrenia. (1987) (59)
- Neuropsychological Test Performance in Healthy Elderly Volunteers Before and After Donepezil Administration: A Randomized, Controlled Study (2005) (59)
- Neuropsychological Test Performance in Healthy Volunteers Before and After Donepezil Administration (2004) (59)
- Clinical Studies of the Cholinergic Deficit in Alzheimer's Disease (1985) (56)
- The relationship between apolipoprotein E, dementia, and vascular illness. (1998) (55)
- Choline chloride treatment of memory deficits in the elderly. (1979) (55)
- Objective psychometric tests in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. (1997) (55)
- Effects of amantadine and trihexyphenidyl on memory in elderly normal volunteers. (1987) (55)
- Eye movement impairment and schizotypal psychopathology. (1994) (55)
- Antemortem markers of Alzheimer's disease (1986) (55)
- Familial patterns of risk in very late-onset Alzheimer disease. (2003) (54)
- Schizophrenia-related and affective personality disorder traits in relatives of probands with schizophrenia and personality disorders. (1993) (53)
- Acetylcholinesterase activity in CSF in schizophrenia, depression, Alzheimer's disease and normals. (1983) (53)
- Assessment of dementia in elderly schizophrenics with structured rating scales (1992) (52)
- Cholinergic drugs in Alzheimer's disease. (1986) (52)
- Verbal learning and memory in schizotypal personality disorder. (1998) (52)
- Olfactory identification deficits in relatives of Alzheimer's disease patients (1996) (51)
- Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patients. (1987) (51)
- Smooth pursuit performance in patients with affective disorders or schizophrenia and normal controls: analysis with specific oculomotor measures, RMS error and qualitative ratings (1995) (51)
- A roadmap for the prevention of dementia: The inaugural Leon Thal Symposium (2008) (50)
- Clinical symptoms associated with age at onset in Alzheimer's disease. (1994) (50)
- Deterioration on the blessed test in Alzheimer's disease: Longitudinal data and their implications for clinical trials and identification of subtypes (1992) (50)
- Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study. (2009) (49)
- Revision of the criteria for Alzheimer's disease: A symposium (2011) (49)
- Age-dependent expression of familial risk in Alzheimer's disease. (1988) (47)
- Lateral ventricular enlargement in schizophrenic probands and their siblings with schizophrenia-related isorders (1998) (47)
- Attentional and eye tracking deficits correlate with negative symptoms in schizophrenia (1997) (47)
- Development of cholinergic drugs for the treatment of Alzheimer's disease (1985) (47)
- Diagnostic issues in chronic schizophrenia: kraepelinian schizophrenia, undifferentiated schizophrenia, and state-independent negative symptoms (1991) (47)
- Seasonal variations of human lumbar CSF neurotransmitter metabolite concentrations (1984) (46)
- Relationship of Disease Severity to Decline on Specific Cognitive and Functional Measures in Alzheimer Disease (1998) (46)
- Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer’s Disease (2015) (45)
- Developing a national strategy to prevent dementia: Leon Thal Symposium 2009 (2010) (45)
- Influence of age and relative weight on cortisol suppression in normal subjects. (1987) (45)
- Anticholinergic Effects on Memory: Benztropine versus Amantadine (1989) (43)
- Scales as outcome measures for Alzheimer's disease (2009) (42)
- The validity of the family history method for identifying Alzheimer disease. (1997) (42)
- Modulation by DLST of the genetic risk of Alzheimer's disease in a very elderly population (1999) (42)
- Short-term haloperidol administration acutely elevates human plasma homovanillic acid concentration. (1987) (42)
- On the utility of P3 latency and RT for studying cognitive processes. (1980) (42)
- Correlation between Abetax-40-, Abetax-42-, and Abetax-43-containing amyloid plaques and cognitive decline. (2001) (41)
- CSF Somatostatin in alzheimer's disease, depressed patients, and control subjects (1988) (41)
- Alzheimer's Disease Assessment Scale: the validation of the scale in Greece in elderly demented patients and normal subjects. (1997) (40)
- Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses. (1984) (40)
- Development and psychometric performance of the schizophrenia objective functioning instrument: An interviewer administered measure of function (2009) (39)
- Choline chloride effects on memory in the elderly (1980) (39)
- Correlates of lateral ventricular size in chronic schizophrenia, II: biological measures. (1986) (38)
- The impact of behavioral impairment of functional ability in Alzheimer's disease (1999) (38)
- Reliability and validity of a chronic care facility adaptation of the Clinical Dementia Rating scale (2001) (38)
- The cholinergic treatment strategy in aging and senile dementia. (1983) (37)
- Neuropsychological assessment of Alzheimer's disease (1997) (37)
- Cholinomimetics and memory. The effect of choline chloride. (1980) (36)
- Assessing changes in Alzheimer's disease: Memory and language. (1986) (35)
- Familial schizophrenia and treatment response. (1987) (34)
- Genetic epidemiological study of maternal and paternal transmission of Alzheimer's disease. (1999) (34)
- Impact of neuroleptic medications on continuous performance test measures in schizophrenia (1996) (34)
- Lack of association between cortisol hypersecretion and nonsuppression on the DST in patients with Alzheimer's disease. (1994) (34)
- Striatal size, glucose metabolic rate, and verbal learning in normal aging. (2003) (34)
- Agitation and postdexamethasone cortisol levels in Alzheimer's disease. (1992) (34)
- Correlation of the clinical severity of alzheimer’s disease with an aberration in mitochondrial DNA (mtDNA) (2001) (33)
- Optimal design of clinical trials for drugs designed to slow the course of Alzheimer’s disease (2006) (33)
- Prevention protocols for Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. (1997) (33)
- Lateral ventricular enlargement in schizotypal personality disorder (1995) (33)
- Age-related differences in formal thought disorder in chronically hospitalized schizophrenic patients: a cross-sectional study across nine decades. (1997) (33)
- Memory impairment in schizophrenic patients with tardive dyskinesia (1988) (32)
- Plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) and clinical symptoms in Alzheimer's disease (1995) (31)
- Performance of chronic schizophrenic patients on cognitive neuropsychological measures sensitive to dementia (1996) (31)
- Future prospects and challenges for Alzheimer's disease drug development in the era of the NIA-AA Research Framework (2018) (30)
- Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease (2015) (30)
- Epidemiological Dementia Index: A Screening Instrument for Alzheimer’s Disease and Other Types of Dementia Suitable for Use in Populations with Low Education Level (1998) (30)
- Kraepelinian schizophrenia: a subgroup of schizophrenia? (1988) (30)
- Age at onset and familial risk in Alzheimer's disease. (1995) (30)
- l-Deprenyl and physostigmine for the treatment of Alzheimer's disease (1995) (30)
- Proof-of-Concept Study to Assess the Nociceptin Receptor Antagonist LY2940094 as a New Treatment for Alcohol Dependence. (2016) (29)
- Activities of daily living as an outcome measure in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. (1997) (28)
- Cerebrospinal fluid acetylcholine, choline, and senile dementia of the Alzheimer's type. (1982) (28)
- Ventricular enlargement associated with linkage marker for schizophrenia-related disorders in one pedigree. (1996) (28)
- Elevated Alpha1-Antichymotrypsin Serum Levels in a Subset of Nondemented First-Degree Relatives of Alzheimer's Disease Patients (1995) (28)
- Cognitive burden and excess Lewy-body pathology in the Lewy-body variant of Alzheimer disease. (2003) (27)
- Partial reversal of anticholinergic amnesia by choline chloride. (1981) (27)
- Leukotomy and aging in chronic schizophrenia: a followup study 40 years after psychosurgery. (1993) (27)
- Cognitive assessment of geriatric schizophrenic patients with severe impairment. (2002) (27)
- Sensitivity of some human cognitive functions to effects of methamphetamine and secobarbital. (1980) (26)
- Oral physostigmine in Alzheimer's disease. (1983) (26)
- A signal detectability analysis of the effect of physostigmine on memory in patients with Alzheimer's disease (1982) (25)
- Apomorphine and schizophrenia. (1984) (23)
- Standardizing the use of the Continuous Performance Test in schizophrenia research: A validation study (2012) (23)
- Statistical power in biological psychiatry (1981) (22)
- Effects of propantheline bromide on basal growth hormone, cortisol and prolactin levels (1983) (22)
- Donepezil preserves functional status in Alzheimer's disease patients: Results from a 1-year prospective placebo-controlled attrition study (1999) (22)
- The clinical syndrome of Alzheimer's disease: aspects particularly relevant to clinical trials (2005) (22)
- Randomized controlled trials in mild cognitive impairment (2017) (21)
- Cholinergic strategies in the treatment of Alzheimer's disease (1991) (21)
- Identifying families with likely genetic protective factors against Alzheimer disease. (1999) (21)
- Validity of the family history method for identifying schizophrenia-related disorders (1997) (21)
- The Special Topics Section of Alzheimer's & Dementia (2015) (20)
- The Effect of Duloxetine Treatment on Cognition in Patients With Fibromyalgia (2012) (20)
- Association of elevated alpha 1-antichymotrypsin with cognitive impairment in a prospective study of the very old. (1998) (20)
- Apolipoprotein E‐η4 allele and familial risk in Alzheimer's disease (1996) (20)
- Research subject recruitment for gerontological studies of pharmacological agents (1982) (19)
- Lecithin and piracetam in Alzheimer's disease (1987) (19)
- Verbal fluency deficits in geriatric and nongeriatric chronic schizophrenic patients. (1997) (19)
- Red blood cell choline. I: Choline in Alzheimer's disease (1985) (19)
- Gamma-hydroxybutyrate in the treatment of schizophrenia (1983) (18)
- Psychobiology of personality disorders: pharmacologic implications. (1987) (17)
- Interaction of choline and scopolamine in human memory. (1985) (17)
- Validity and utility of the ADAS-L for measurement of cognitive and functional impairment in geriatric schizophrenic inpatients. (1995) (17)
- Methamphetamine and diphenhydramine effects on the rate of cognitive processing (1978) (17)
- Choline chloride effects on memory: Correlation with the effects of physostigmine (1980) (17)
- Apomorphine has no effect on plasma homovanillic acid in schizophrenic patients (1985) (16)
- Clinical correlates of platelet prostaglandin receptor subsensitivity in schizophrenia. (1987) (16)
- Multicenter Evaluation of New Instruments for Alzheimer's Disease Clinical Trials: Summary of Results (1997) (16)
- Memory functions in geriatric chronic schizophrenic patients: a neuropsychological study. (1995) (16)
- Evaluating prolactin response to dopamine agonists in schizophrenia. Methodological problems. (1985) (15)
- Slowing of short-term memory scanning in alcoholics. (1978) (15)
- Effects of short-term memory contents on short-and long-term memory searches (1973) (15)
- Anticholinergic effects on memory: benztropine vs. amantadine. (1987) (15)
- A cross‐cultural family history study of primary progressive dementia in relatives of nondemented elderly Chinese, Italians, Jews and Puerto Ricans (1992) (15)
- Alzheimerʼs disease: morbid risk among first-degree relatives approximates 50% by 90 years of age (1987) (15)
- Neurofibrillary tangles, Alzheimer's disease, and Lewy bodies (1990) (15)
- Correlation between Cognition and Function across the Spectrum of Alzheimer's Disease. (2016) (14)
- Naloxone does not affect pain sensitivity, mood or cognition in patients with high levels of beta-endorphin in plasma. (1982) (14)
- in Patients With Alzheimer's Disease (1987) (14)
- A study of the reliability of reported premorbid adjustment in schizophrenic patients. (1984) (14)
- Search Processes for Associative Structures in Long-Term Memory. (1975) (13)
- Red blood cell choline. II: Kinetics in alzheimer's disease (1985) (13)
- Intracerebral des-tyrosine-γ-endorphin inhibits methylphenidate induced locomotor activity (1981) (13)
- The effect of lithium on rat brain and erythrocyte glycine levels. (1981) (12)
- Evaluating semagacestat, a gamma-secretase inhibitor, in a phase III trial (2011) (12)
- A simulation study comparing slope model with mixed-model repeated measure to assess cognitive data in clinical trials of Alzheimer's disease (2018) (12)
- Cognition in Schizophrenia: Natural History, Assessment, and Clinical Importance (1999) (11)
- Longitudinal changes: Cognitive, behavioral, and affective patterns in Alzheimer's disease. (1986) (11)
- Elevated alpha 1-antichymotrypsin serum levels in a subset of nondemented first-degree relatives of Alzheimer's disease patients. (1995) (11)
- Eye tracking, schizophrenic symptoms, and schizotypal personality disorder (2005) (11)
- Neurotransmitter Deficits in Alzheimer's Disease: Criteria for Significance (1983) (10)
- 5 – Memory Changes with Aging and Dementia (2001) (10)
- No support for linkage to the bipolar regions on chromosomes 4p, 18p, or 18q in 43 schizophrenia pedigrees. (2000) (10)
- Apolipoprotein E genotype and cognition in the very old (1997) (10)
- COGNITIVE IMPAIRMENT PRECEDES AND PREDICTS FUNCTIONAL IMPAIRMENT IN MILD ALZHEIMER'S DISEASE (2014) (10)
- The Alzheimer’s Disease Assessment Scale: Modifications That Can Enhance its Use in Future Clinical Trials (1997) (10)
- Cholinergic drug effects on memory and cognition in humans. (1980) (10)
- Clinical genetic studies of Alzheimer's disease. (1991) (10)
- 133 Lateral ventricular enlargement in schizophrenic probands and their siblings with schizophrenia-related disorders (1997) (9)
- Lack of association between clinical symptoms and postmortem indices of brain serotonin function in Alzheimer's disease (1995) (9)
- Intravenous and Oral Physostigmine in Alzheimer’s Disease (1985) (9)
- Assessing cognitive function in schizophrenics and patients with Alzheimer's disease (1995) (9)
- Value-Generating Exploratory Trials in Neurodegenerative Dementias (2021) (8)
- Neuroendocrine dysfunction in Alzheimer's disease: results following TRH stimulation (1992) (8)
- A phase I study of AIT-082 in healthy elderly volunteers (2007) (8)
- Post-mortem examination of dopaminergic parameters in Alzheimer's disease: Relationship to noncognitive symptoms (1993) (8)
- Development of the Korean Version of Alzheimers Disease Assessment Scale(ADAS-K) to Assess Cognition in Dementia (2003) (8)
- Plasma Homovanillic Acid and Performance on Motor and Cognitive Tasks in Community-Dwelling Elderly: MacArthur Studies of Successful Aging (1994) (8)
- A perspective on risks that impede development of drugs to modify the course of Alzheimer’s disease: Can they be reduced? (2008) (8)
- Frontal functioning and plasma HVA in the relatives of schizophrenic patients (1992) (8)
- Apolipoprotein E-epsilon 4 allele and familial risk in Alzheimer's disease. (1996) (7)
- Dopaminergic dysregulation in schizophrenia: A target for new drugs (1986) (7)
- Memory impairment in amnesia and dementia: implications for the use of animal models. (1988) (7)
- Correlation Between A x40 – , A x-42 – , and A x-43 – Containing Amyloid Plaques and Cognitive Decline (2002) (7)
- Physostigmine in patients with Alzheimer's disease. (1986) (6)
- Morbid Risk to First Degree Relatives of Neuropathologically Confirmed Cases of Alzheimer's Disease (1992) (6)
- Human memory and the effects of physostigmine and choline chloride [proceedings]. (1980) (6)
- Glucose metabolic rate and progression of illness in Alzheimer's disease (1995) (6)
- Analysis of the Relationship of Cognitive Impairment and Functional Impairment in Mild Alzheimer’s Disease in EXPEDITION 3 (2018) (6)
- Has familial aggregation in Alzheimer's disease been overestimated? (2000) (6)
- The effects of amantadine vs. trihexyphenidyl on memory in elderly normal volunteers. (1987) (5)
- Anticholinergic dementia as a model of Alzheimer's disease. (1986) (5)
- Electrophysiological Effects of Physostigminein Humans (1979) (5)
- A Brief Telephonic Instrument to Screen for Cognitive Impairment in a Managed Care Population (2003) (5)
- Effects of debrisoquin on plasma homovanillic acid concentration in schizophrenic patients. (1987) (5)
- Improving Early Recognition of Alzheimer's Disease: A Review of Telephonic Screening Tools (2001) (5)
- New thinking about thinking, part two. Theoretical articles for Alzheimer's & Dementia (2018) (5)
- Toward a consensus recommendation for defining the asymptomatic-preclinical phases of putative Alzheimer's disease? (2016) (5)
- Effect of apomorphine infusion on plasma homovanillic acid in normal subjects. (1986) (5)
- Platelet phospholipid synthesis in Alzheimer's disease (1991) (5)
- Cognitive decline in geriatric chronic schizophrenic patients: evidence for a neurodegenerative process? (1996) (4)
- HOPE4MCI trial: First trial targeting reduction of hippocampal overactivity to treat mild cognitive impairment due to Alzheimer’s disease with AGB101 (2020) (4)
- Recognition time for words in short-term, long-term or both memory stores (1974) (4)
- Age dependent change of ventricular measures in schizophrenia: Cross-sectional analysis (1994) (4)
- Assessment of Cognition and Affective Symptoms in Dementia (1985) (4)
- Genome scan of schizophrenia: Results of genotyping of positive regions. (1999) (4)
- 82 ALZHEIMER DISEASE : FROM EARLIEST SYMPTOMS TO END STAGE (2002) (4)
- AlzheimerâÂÂs and ParkinsonâÂÂs Diseases Face Common Challenges inTherapeutic Development: Role of the Precompetitive Consortium,Coalition Against Major Diseases (2015) (4)
- EEG effects of physostigmine and choline chloride in humans (1979) (3)
- A rationale for studying the transmissibility of Alzheimer's disease (1982) (3)
- Assessing Symptom Severity in Alzheimer’s Disease1 (1985) (3)
- Cholinomimetic Agents and Human Memory: Preliminary Observations in Alzheimer’s Disease (1981) (3)
- Human and Animal Studies With Cholinergic Agents: How Clinically Exploitable is the Cholinergic Deficiency in Alzheimer’s Disease (1986) (3)
- The Treatment of Memory Deficits in the Aged with Choline Chloride (1979) (3)
- Alzheimer's disease: Tacrine and tacrine metabolite concentrations in plasma and cognitive change (1995) (3)
- Convergence of cognitive and adaptive decline in chronic schizophrenia (1998) (3)
- Cognitive Effects of Physostigmine and Choline Chloride in Normal Subjects (1979) (3)
- Elevated amyloid β-peptides in brain: Correlation with cognitive decline (2000) (3)
- symptom correlates of poor eye tracking in patients with schizotypal personality disorder and relatives of schizophrenic probands (1989) (2)
- Neuroimaging, neurobiological, and neuropsychological abnormalities in SPD: Implications for a model of the schizophrenia spectrum (1995) (2)
- Methodological aspects of evaluating effects of AD progression (1995) (2)
- The importance of mitochondrial damage in Alzheimer's disease varies according to APOE genotype (2000) (2)
- Erratum: A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies. (2016) (2)
- DEMENTIA‐LIKE SYMPTOMS IN ELDERLY SCHIZOPHRENIC PATIENTS (1992) (2)
- P4-379: Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple-dose administration of a gamma-secretase inhibitor in Japanese subjects (2008) (2)
- First quarter births in Alzheimer's disease. (1993) (2)
- COGNITION IMPAIRMENT PRECEDES AND PREDICTS FUNCTIONAL IMPAIRMENT IN MILD ALZHIEMER’S DISEASE (2014) (2)
- Genetic studies of typical Alzheimer's disease (1989) (2)
- Risk of Alzheimer's Disease in First-Degree Relatives-Reply (1995) (2)
- Efficacy and Safety of Intravenous Solanezumab in Patients with Mild to Moderate Alzheimer's Disease: Results of Two Phase 3 Studies (2013) (2)
- Effects of solanezumab versus placebo administration on biomarkers in people with mild-to-moderate Alzheimer's disease: Results from two phase III clinical trials (2013) (1)
- Processing multiple recognition probes in short- and long-term memory (1975) (1)
- Intracerebral des-tyrosine-gamma-endorphin inhibits methylphenidate induced locomotor activity. (1981) (1)
- Hypercortisolism and Brain Ventricular Size in Normal Aging and Alzheimer's Disease. (1994) (1)
- 327 Cognitive impairment and clinical symptoms in geriatric schizophrenic patients: Differences associated with overall outcome (1997) (1)
- Psychological assessment of the elderly (2019) (1)
- The Use of Tests and Instruments in the Evaluation of Patients With Dementia (1996) (1)
- Donepezil: A Viewpoint (1997) (1)
- Relations among eye tracking, CPT, and backward masking deficits in schizophrenic patients and their relatives (1989) (1)
- ASSESSMENT OF COGNITION IN THE OLDER ADULT WITH SCHIZOPHRENIA: THE DEMENTIA OF DEMENTIA PRAECOX (1999) (1)
- Antipsychotic Efficacy of Fluotracen: A Clinical Trial (1983) (1)
- 564. Indices of early dementia: neuropsychological and behavioral indices (2000) (1)
- Sequential search processes in long-term memory (1976) (1)
- Commentary on “Diagnosis of Alzheimer’s disease: Two decades of progress” (2005) (1)
- 288 Cognitive decline in geriatric schizophrenic inpatients (1997) (1)
- Morbid Risk in First-Degree Relatives of Persons With Alzheimer's Disease-Reply (1988) (1)
- State and trait components of negative symptoms within schizophrenic patients (1989) (1)
- The Alzheimer's Disease Centers' Neuropsychological Database Initiative: A Resource for Alzheimer's Disease Prevention Trials (2002) (1)
- Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease (2015) (0)
- Bio‐Hermes: A Validation Study to Assess a Meaningful Relationship Between Blood and Digital Biomarkers with Aβ PET Scans for Alzheimer’s Disease (2022) (0)
- Psychopharmacology and neurotransmitter systems in the elderly (1981) (0)
- Treatment of Dementia with Vasoactive Drugs (1988) (0)
- A linkage marker for schizophrenia and related disorders (1994) (0)
- INNOVATIONS IN CLINICAL TRIALS: IMPROVING STUDY START UP (SSU) (2018) (0)
- Correlation between Aβ42 deposition and clinical demetia (2000) (0)
- Plasma HVA correlates of attentional performance in unmedicated schizophrenics (1991) (0)
- 382. Cognitive impairment in elderly schizophrenics: Phenomenology, longitudinal course, and neuropathology (1996) (0)
- Challenges and progress in research, diagnostics, and therapeutics in Alzheimer's disease and related dementias (2022) (0)
- Brief Screen for Cognitive Impairment (2018) (0)
- Contents of The American Journal of Psychiatry (1987) (0)
- Boosting Memory in Alzheimerʼs (1983) (0)
- Heterogeneity in undifferentiated schizophrenia (1989) (0)
- BIOLOGIC MARKERS IN DSM-III DIAGNOSED PERSONALITY DISORDERS (1984) (0)
- P2-389 EMPLOYING LYMPHOCYTE PROLIFERATIONAS A MEANS TO ASSESS CELL CYCLE DYSREGULATION IN COGNITIVELY IMPAIRED SUBJECTS: CLINICAL PERFORMANCE OF THE LYMPRO ASSAY (2014) (0)
- Optic nerve head in Alzheimer's disease patients (1989) (0)
- 187. Indices of early dementia (2000) (0)
- THE CHALLENGE OF AD TRIAL ENROLLMENT: CAN SITE CAPACITY MEET THE URGENT DEMAND? (2018) (0)
- Metabolic changes with age in schizophrenia (1997) (0)
- Alzheimer's and Parkinson's disease. New drug development, and innovative experimental approaches (1986) (0)
- A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies (2016) (0)
- The Schizophrenia Biologic Research Centers of the Veterans Administration (1984) (0)
- Donepezil improved cognitive and global function in mild-to-moderate Alzheimer disease (1998) (0)
- News Briefs (1988) (0)
- The relationship between working memory deficits and other measures sensitive to prefrontal dysfunction (1995) (0)
- Chronic Schizophrenia, II: Biological Measures (1986) (0)
- Prospective Genetic Epidemiology of Dementia in the Very Old (1998) (0)
- Major considerations in conducting a global phase III registration study in Alzheimer's disease (2009) (0)
- An investigation of HCV as a predictor of cognitive decline: The Bio‐Hermes protocol (2021) (0)
- Using family history screening for linkage studies in schizophrenia (1989) (0)
- P1–341: Withdrawn (2013) (0)
- THE INTERFACE OF NEUROPSYCHIATRIC DISORDERS, DIAGNOSIS, AND TREATMENT: AN INTERNATIONAL PERSPECTIVE (1999) (0)
- GAP rater certification program transforms the rater certification process (2020) (0)
- REMOVING BARRIERS TO ALZHEIMER'S DISEASE CLINICAL TRIAL EXECUTION: GAP RATER CERTIFICATION PROGRAM (2019) (0)
- List of contributors (2019) (0)
- Cognitive impairment in Alzheimers disease and schizophrenia (1998) (0)
- Contents of the American Journal of Psychiatry (1992) (0)
- Neuroendocrine abnormalities in Alzheimer's disease: TRH test (1989) (0)
- 172. Factor structure of schizotypy in relatives of schizophrenia patients (1996) (0)
- BJP volume 151 issue 5 Cover and Back matter (1987) (0)
- Phosphorylated cyclin dependent kinase 4-like-immunoreactivity is specifically expressed in vulnerable neurons of Alzheimers disease at its earliest (1998) (0)
- Electrophysiological Effects of Choline Chloride in Elderly Subjects (1979) (0)
- NOVEL RECRUITMENT STRATEGIES FOR CLINICAL TRIALS: A PRELIMINARY REPORT FROM THE GLOBAL ALZHEIMER’S PLATFORM NETWORK (GAP-NET) (2017) (0)
- Instruments for Measuring the Efficacy of Treatments for Alzheimer’s Disease (1994) (0)
- Neuroleptic effects on CPT and eye tracking in schizophrenia (1994) (0)
- Contents of the American Journal of Psychiatry (1993) (0)
- 374 Prospective genetic epidemiology of cognitive performance in the very old (1996) (0)
- Visuospatial working memory deficits in schizophrenia (1993) (0)
- Schizophrenia Outcomes Functioning Interview--Informant Version (2012) (0)
- Delayed word recall in aged schizophrenia (1994) (0)
- 560. Indices of early dementia: neuropathological indices (2000) (0)
- The placebo data analysis in Alzheimer's disease and mild cognitive impairment (MCI) clinical trials project: Overview of progress in trial data collection, and key findings from the pooled MCI trial datasets (2012) (0)
- Disorders of Brain and Mind (1999) (0)
- CERAD (Consortium to Establish a Registry for Alzheimer's Disease) Neuropsychology Assessment Battery: 35 Years and Counting. (2023) (0)
- Dr. Greenwald and Associates Reply (1987) (0)
- Cognitive impairment is not influenced by α1-antichymotrypsin genotype in the very old (1996) (0)
- Is very late onset Alzheimer's disease influenced by genetic factors? (2000) (0)
- Bayesian Longitudinal Modeling on Placebo Data from Alzheimer’s Disease Clinical Studies (P1.010) (2014) (0)
- Dopaminergic correlates of attentional performance in unmedicated schizophrenic patients (1992) (0)
- REVISING THE ADMINISTRATION OF THE ADAS-COG (2014) (0)
- Apolipoprotein E allele ϵ4 in autopsy-confirmed Alzheimer's disease and cerebrovascular disease (1994) (0)
- O-20-8 Prospective study of the effect of APOE genotype on cognitive performance in the very old (1996) (0)
- Apomorphine's Antipsychotic Activity-Reply (1985) (0)
- 293 Cognitive function and psychotic symptoms in geriatric schizophrenia (1997) (0)
- Alzheimer's: Making progress in the progressive dementia (Roundtable). (1993) (0)
- Schizophrenia Outcomes Functioning Interview--Patient Version (2012) (0)
- P-8-9 Apolipoprotein E genotype and clinical measures of dementia (1995) (0)
- Relatives of Schizophrenic (1994) (0)
- Cognitive and Functional Decline and their Relationship in Patients with Mild Alzheimer’s Disease (P3.208) (2014) (0)
- Clinical and neuroendocrine correlates of hypercortisolemia in Alzheimer's disease (1989) (0)
- Chapter 22 – Psychological Assessment of the Elderly (2000) (0)
- Alzheimerʼs disease and related dementias (1994) (0)
- ADAPTATION AND VALIDATION OF THE ALZHEIMER'S DISEASE ASSESSMENT SCALE (ADAS-COG) FOR THE COLOMBIAN POPULATION (2014) (0)
- 543. Lateral and medial temporal Lobe metabolic rate in Alzheimer's disease (1996) (0)
- Authors' response to commentaries on Hollander et al. antemortem marker paper (1986) (0)
- The authors reply (1992) (0)
- How do different economic models of care impact the care of patients with dementia ? (2003) (0)
- Responses to Clonidine in Acute and Remitted Depressed Patients (1986) (0)
- Apolipoprotein ɛ4 allele and familial risk in Alzheimer's disease (1994) (0)
- Psychometric comparison of standard and computerized administration of the Alzheimer's Disease Assessment Scale (ADAS) among patients with mild-to-moderate Alzheimer's disease (2010) (0)
- 369. Cognitive impairment in Alzheimer's disease and schizophrenia (1998) (0)
- HOPE4MCI trial: First trial targeting reduction of hippocampal overactivity to treat mild cognitive impairment due to Alzheimer’s disease with AGB101 (2021) (0)
- DIFFUSE PLAQUE FORMATION IN THE CEREBRAL CORTEX: NEUROPATHOLOGIC OBSERVATIONS AND CORRELATION WITH COGNITIVE STATUS IN A LARGE AUTOPSY-BASED SERIES (1998) (0)
- Effects of Intravenous Solanezumab 400 mg q 4 Weeks vs. Placebo on Biomarkers in Patients with Mild to Moderate Alzheimer's Disease: Results of Two Phase 3 Studies (P01.011) (2013) (0)
- A reexamination of schizophrenia subtypes (1989) (0)
- 562. Indices of early dementia: neocortical levels of amyloid β-peptide (2000) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Richard C. Mohs?
Richard C. Mohs is affiliated with the following schools:
